Background: To explore the correlation between bone metastasis and laboratory examination such as cholesterol level in patients with lung adenocarcinoma. Method: Medical records were studied for patients who were admitted into this high-volume institution from Jan 1, 2017 to the present. 114 patients diagnosed and treated as esophageal squamous cell carcinoma with bone metastasis were retrospectively analyzed for the present study. Along with them were 114 patients without bone metastasis in the control group. Result: There was no significant statistical difference between groups with respect to neutrophils count, lymphocyte count, monocyte count, bilirubin, calcium ion, phosphorus, or blood sugar. Univariable analysis found that total cholesterol levels (OR: 0.230; 95% CI: 0.064e0.822; P¼0.024) and triglyceride levels (OR: 0.001; 95% CI: 0.000e0.201; P¼0.012) , and Multivariate analysis indicated that triglyceride levels (OR: 0.001; 95% CI: 0.000e0.327; P¼0.020) were independently associated with development of bone metastasis in patients with lung adenocarcinoma. Conclusion: Triglyceride levels were independently associated with the development of bone metastasis in patients with lung adenocarcinoma.
Background: The treatment landscape for EGFR M+ stage IIIb/IV NSCLC has significantly changed in the past few years: at the end of 2015, 3rd generation TKI osimertinib was approved for the treatment of EGFR T790M+ NSCLC, and in 2018, osimertinib was approved for the first-line treatment of EGFR M+ patients. As such, there is much debate amongst oncologists around which TKI to prescribe to patients first, now that more targeted treatments are available. The aim of this study was to assess current attitudes towards decision making for TKI sequencing to determine what matters most when selecting a treatment and what challenges oncologists face. Method: A representative online survey was conducted with 310 HCPs (Oncologists, Pulmonologists, Respiratory Surgeons and Internal Respiratory Specialists) across four countries (China, Germany, Japan and USA) between April 2018 and May 2018. Result: For all four countries and irrespective of treatment line, increasing overall survival (OS), followed by increasing quality of life (QoL) emerged as the most important treatment ambitions when prescribing TKIs. However, examination of treatment goals in the first-line setting revealed that clinically meaningful OS stands out for the US, Germany and Japan. In contrast for China, offering a clinically meaningful progression-free survival (PFS), OS, and improved health related QoL appear to be of equal importance. Predictability of treatment outcome in first-line therapy was also a relevant influence on treatment choice. This included a predictable pattern of resistance to TKIs for the majority of patients, efficacy in specific EGFR M+ subtypes, availability in flexible dose adjustment and if a compound was part of a sequence of targeted treatments which may delay time to chemotherapy. In terms of the sequencing of TKIs, 55% strongly prefer a treatment sequence offering maximum time on targeted therapies. Furthermore, there is a strong need across all countries for information on potential resistance mutations before changing current treatment practice e and over a third (36%) of all HCPs agreed that they do not feel they have all the data required to make informed decisions on how to sequence EGFR M+ NSCLC treatments. Conclusion: The study confirms that increasing survival time across treatment lines is the overarching ambition when using TKIs in EGFR M+ NSCLC together with increasing QoL. In order to overcome uncertainties regarding the appropriate treatment decisions for patients EGFR M+ NSCLC, HCPs require more information about the possible impact of treatment sequencing on extending survival. October 2018 Abstracts S907
Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX/US Background: Patient-Reported Outcomes (PROs) provide information on patient treatment experience. We have established a real-world Advanced Non-Small Cell Lung Holistic Registry (ANCHoR) to understand how the advent of immunotherapy impacts treatment choice, clinical outcomes, and PROs of metastatic non-small cell lung cancer (mNSCLC). The aim of this analysis is to report early results of baseline symptom status and quality of life among mNSCLC patients using the MD Anderson Symptom Inventory lung cancer module (MDASI-LC) and EuroQol-5D 5-level version (EQ-5D-5L). Method: During 2017, patients with mNSCLC at a single institution were enrolled in ANCHoR and completed the PRO questionnaires at clinic visits. MDASI-LC consists of thirteen core and three lung cancer-specific symptom severity questions, and six interference items rated on 0-10 scales (0 ¼ no symptom or interference, 10 ¼ worst imaginable symptom or complete interference). EQ-5D-5L captures five health state dimensions: mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression rated on a five-level scale (1¼ no problems, 5¼ extreme problems). A single visual analogue scale (VAS) on EQ-5D-5L records patient self-rated health between "best imaginable" (100) and "worst imaginable" (0) health state. Descriptive statistics for PRO scores at baseline are summarized. Result: Forty-two patients completed baseline PROs before the start of therapy. Mean patient age was 63 years and 45% were males. For MDASI-LC, the mean scores for the core symptom, lung cancer-specific symptom, and interference subscales at baseline were 2.2 (standard deviation [SD] ¼ 2.80), 2.1 (SD ¼ 2.80), and 2.8 (SD ¼ 3.10), respectively. Fatigue was the most severe symptom reported at baseline (mean ¼ 4.1, SD ¼ 3.01), followed by shortness of breath (mean ¼ 3.2, SD ¼ 2.81) and pain (mean ¼ 3.19, SD ¼ 3.00). The highest percentages of patients reporting moderate to severe symptom levels (score of 5) were 38% for fatigue, 33% for pain, 31% for drowsiness, 29% for shortness of breath and disturbed sleep, and 26% coughing. For EQ-5D-5L, 91% of patient reported problems with selfcare, 81% with mobility, 48% with usual activity and anxiety, and 33% with pain. Mean EQ-5D VAS was 73.9 (SD ¼ 18.2). Conclusion: Prior to the start of treatment, fatigue, pain, drowsiness, disturbed sleep, and coughing were the most common symptoms with fatigue, shortness of breath, and pain being the most severe. Additional follow up will confirm and expand these findings and will also allow us to examine change in PROs after first-line treatment is administered. Background: Recent randomized clinical trials (RCTs) have explored survival benefits of second-line treatments (2LTs) in patients who have rapidly progressed and/or are refractory to first-line treatment, and these trials have determined an existing unmet need for these patients with aggressive non-small cell lung cancer (NSCLC). However, specific characterization of aggressive NSCLC is lacking, thus a systematic literature review was conducted to explore the definitions of aggressive NSCLC. Method: We systematically searched Medline, Embase, Bio-Sciences Information Service, the Cochrane Library, and abstracts from scientific meetings (through October 2017) to identify RCTs reporting the efficacy and/or safety of select 2LTs in patients with advanced NSCLC who have characteristics associated with aggressive disease (AD). Six potential overarching categorizations of these characteristics (based on expert clinical opinion) were explored: (1) refractory and/or progressive disease as best response to prior treatment, (2) rapid progression, (3) short duration on previous treatment, (4) high tumor burden or size, (5) short duration since start of last treatment, and (6) high symptom burden. Result: The 14 identified studies had one or more subgroups within five of the six categorizations (11, 2, 1, 2, and 4 studies presented subgroups within categories 1-5, respectively). No RCTs presenting a subgroup of patients for category 6 were identified. Within each category, the identified subgroup definitions varied (15, 4, 3, 2, and 7 different definitions within categories 1-5, respectively). Reporting of whether a subgroup was prespecified or not was limited and often unclear; 6 studies indicated that subgroup analyses of patients with AD characteristics were preplanned. Moreover, baseline characteristics for the subgroup of patients with AD were often not reported. Conclusion: Definitions of AD varied, both across the identified studies of 2LTs and within the predetermined categorizations, with refractory being the most frequent followed by short duration since start of last treatment. With the emerging clinical importance of AD, more standard use of these definitions within RCTs may allow for greater comparison across 2LTs and will enable indirect treatment comparisons of the results. As with any subgroup, clarity on preplanned versus post hoc analysis is important for interpretation and should be specified. Additional studies powered to assess treatment benefits in advanced NSCLC patients with AD are needed. 
